NCT05980416

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Express CLDN18.2

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 88 (actual)
• Sponsor: Elevation Oncology · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.

Conditions

• Stomach Neoplasm
• Gastrointestinal Neoplasms
• Digestive System Neoplasm
• Neoplasms by Site
• Neoplasms

Interventions

Type	Name	Description
DRUG	EO-3021	Anti-Claudin 18.2 antibody drug conjugate
DRUG	Ramucirumab (CYRAMZA®)	VEGFR2 inhibitor
DRUG	Dostarlimab	anti-PD-1 antibody

Timeline

• Start date: 2023-08-10
• Primary completion: 2025-05-07
• Completion: 2025-06-02
• First posted: 2023-08-08
• Last updated: 2025-11-14
• Results posted: 2025-11-14

Locations

20 sites across 3 countries: United States, Japan, South Korea

Regulatory

• FDA-regulated drug study